Our previous studies demonstrated that the expression of EFHD2 is not only significantly associated with postsurgical recurrence in patients with stage I NSCLC [10], but also increases NSCLC resistance to cisplatin through activating the NOX4-ROS-ABCC1 signaling pathway [11]. This evidence concerns the gene EFHD2 and non-small cell lung carcinoma.